Hematology and Oncology
Parent: Medical Student Research Forum Posters
eScholarship stats: Breakdown by Item for December, 2024 through March, 2025
| Item | Title | Total requests | Download | View-only | %Dnld |
|---|---|---|---|---|---|
| 54q9h3d9 | Low Income Areas Predict T Stage in Patients with Head and Neck Cancer | 32 | 1 | 31 | 3.1% |
| 52n3v75r | Feasibility of a Symptomatic Screening Program for Early Detection of Gastric Cancer in Roatan, Honduras: Preliminary Results | 31 | 12 | 19 | 38.7% |
| 83v9859d | Pathogenesis of Endometriosis in Non-Human Primates: A Critical Literature Review | 25 | 4 | 21 | 16.0% |
| 0fr155c7 | MEK Inhibitor-Based Combination Strategies in Selected Molecular Subsets of Non-Small Cell Lung Cancer (NSCLC): rationale for the Design of Phase I Clinical Trials | 24 | 3 | 21 | 12.5% |
| 07k290bw | Analyzing gene expression in androgen resistant prostate cancer | 22 | 4 | 18 | 18.2% |
| 65p3521q | Sarcopenia and Frailty as Predictors of Surgical Morbidity and Oncologic Outcomes in Retroperitoneal Sarcoma | 22 | 7 | 15 | 31.8% |
| 1kh858pm | Fragmentation of Care for Young Adults with Sickle Cell Disease in California | 21 | 2 | 19 | 9.5% |
| 2w0363m2 | Views of Non-Physician Stakeholders on Barriers & Facilitators to AYA Cancer Care in Latin America | 19 | 3 | 16 | 15.8% |
| 0009k5hn | Developing PRISM-Spanish: A psychosocial skills-based intervention for Spanish-speaking adolescents and young adults with cancer | 18 | 3 | 15 | 16.7% |
| 3fj8d062 | Investigating the role of saposin B in HMA-mediated toxicity toward breast cancer cells | 16 | 0 | 16 | 0.0% |
| 2vc3315r | Amiloride Derivative Compound 10357 in the Treatment of B-Cell Acute Lymphoblastic Leukemia | 15 | 3 | 12 | 20.0% |
| 3990f2bj | Which non-phamacologic interventions are most effective at addressing chemotherapy related cognitive impairment (CRCI) in adolescent and young adult cancer survivors? | 15 | 2 | 13 | 13.3% |
| 6kw1t6b1 | An Integrated Multidisciplinary Evaulation Platform and Early Experience for Precision Therapy in Resectable NSCLC | 14 | 3 | 11 | 21.4% |
Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.